Literature DB >> 12875940

The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer.

G van Andel1, K H Kurth.   

Abstract

PURPOSE: To evaluate the impact of androgen deprivation on health related quality of life (HRQOL) in patients with asymptomatic lymph node positive prostatic carcinoma (LPPC).
MATERIALS AND METHODS: HRQOL domains were measured, using standard instruments in 91 patients with histologically proven LPPC. Most patients were randomized for immediate or deferred hormonal treatment until progression was observed. For analyses concerning the time to progression and survival the Kaplan-Meier method was used.
RESULTS: Patients treated with androgen deprivation showed a significantly worse sexual, emotional, and physical function, experienced more hot flushes and a worse overall HRQOL, compared with patients receiving no therapy. Time to progression was significantly shorter in the deferred treated patients in comparison with the immediately treated patients (33 vs. 62 months, p<0.001). No significant differences were found with respect to the duration of survival.
CONCLUSION: Hormonally treated patients with asymptomatic LPPC have a worse HRQOL compared with patients receiving no therapy. The duration of survival was similar, whether patients received immediate or deferred hormonal treatment. Nowadays, with patients' preferences playing an increasingly important role in therapeutic decision making, physicians should be aware of this negative impact and ought to inform the patients on this.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875940     DOI: 10.1016/s0302-2838(03)00208-2

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

1.  Passing through the wall: on outings, exodus, angels, and the ark.

Authors:  Richard Joel Wassersug
Journal:  J Relig Health       Date:  2008-12-30

2.  Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.

Authors:  Thiago Gagliano-Jucá; Thomas G Travison; Paul L Nguyen; Philip W Kantoff; Mary-Ellen Taplin; Adam S Kibel; Robert Manley; Kathleen Hally; Richelle Bearup; Yusnie M Beleva; Grace Huang; Robert R Edwards; Shehzad Basaria
Journal:  J Pain Symptom Manage       Date:  2017-09-21       Impact factor: 3.612

Review 3.  Management of fatigue in cancer patients.

Authors:  Mellar P Davis; Dilara Khoshknabi; Guang H Yue
Journal:  Curr Pain Headache Rep       Date:  2006-08

4.  Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate?

Authors:  Hao Lun Luo; Fu Min Fang; Chih Hsiung Kang; Yao Chi Chuang; Po Hui Chiang
Journal:  Int Urol Nephrol       Date:  2012-09-13       Impact factor: 2.370

Review 5.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

Review 6.  [Plastic surgery for the treatment of gynaecomastia following hormone therapy in prostate carcinoma].

Authors:  H Ryssel; G Germann; E Köllensperger; K Riedel
Journal:  Urologe A       Date:  2008-04       Impact factor: 0.639

7.  Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.

Authors:  William F Pirl; Joseph A Greer; Melissa Goode; Matthew R Smith
Journal:  Psychooncology       Date:  2008-02       Impact factor: 3.894

Review 8.  Optimal management of recurrent prostate cancer in older patients.

Authors:  Elizabeth R Kessler; Thomas W Flaig
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923

9.  Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.

Authors:  William Dale; Joshua Hemmerich; Kathryn Bylow; Supriya Mohile; Mary Mullaney; Walter M Stadler
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis.

Authors:  Wen Liu; Yu Yao; Xue Liu; Yong Liu; Gui-Ming Zhang
Journal:  Asian J Androl       Date:  2021 Jul-Aug       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.